{
  "author": {
    "name": "James Paton",
    "webUrl": "/author/profile/james-paton/",
    "description": "",
    "imageLarge": "https://secure.gravatar.com/avatar/f16d6fc2845f417ea0e93a3f2b6cd37d?s=136&d=mm&r=g",
    "estimate": 5,
    "social": [],
    "articles": [
      {
        "uri": "/2019/12/04/amazon-teams-up-with-novartis-on-pharma-delivery/",
        "title": "Amazon teams up with Novartis on pharma delivery",
        "byline": "James Paton",
        "kicker": "News",
        "prettyDate": "December 04, 2019",
        "timeToRead": "2 minute",
        "image": {
          "uri": "https://images.benefitspro.com/contrib/content/uploads/sites/412/2018/06/amazon2.jpg",
          "width": "600",
          "height": "400"
        },
        "authors": [
          {
            "webUrl": "/author/profile/james-paton/",
            "name": "James Paton"
          }
        ],
        "kickerNode": [
          {
            "uri": "/news/",
            "sectionName": "News"
          }
        ],
        "summary": "The partnership aims to make the manufacturing and delivery of new medicines more efficient.",
        "body": null
      },
      {
        "uri": "/2019/05/29/fda-approves-2-1-million-gene-therapy-drug/",
        "title": "FDA approves $2.1 million gene therapy drug",
        "byline": "James Paton and Michelle Fay Cortez",
        "kicker": "News",
        "prettyDate": "May 29, 2019",
        "timeToRead": "5 minute",
        "image": {
          "uri": "https://images.benefitspro.com/contrib/content/uploads/sites/412/2018/04/DrugVials.jpg",
          "width": "600",
          "height": "400"
        },
        "authors": [
          {
            "webUrl": "/author/profile/james-paton/",
            "name": "James Paton"
          },
          {
            "webUrl": "/author/profile/michelle-fay-cortez/",
            "name": "Michelle Fay Cortez"
          }
        ],
        "kickerNode": [
          {
            "uri": "/news/",
            "sectionName": "News"
          }
        ],
        "summary": "Zolgensma, the first drug in the U.S. to cross the $1 million mark, is an important test for the field as a wave of gene therapies advance.",
        "body": null
      },
      {
        "uri": "/2019/05/16/drugmakers-turning-attention-to-apps-and-digital-treatments/",
        "title": "Drugmakers turning attention to apps and digital treatments",
        "byline": "James Paton",
        "kicker": "News",
        "prettyDate": "May 16, 2019",
        "timeToRead": "3 minute",
        "image": {
          "uri": "https://images.benefitspro.com/contrib/content/uploads/sites/412/2018/04/PhoneApp2.jpg",
          "width": "616",
          "height": "372"
        },
        "authors": [
          {
            "webUrl": "/author/profile/james-paton/",
            "name": "James Paton"
          }
        ],
        "kickerNode": [
          {
            "uri": "/news/",
            "sectionName": "News"
          }
        ],
        "summary": "As costs to develop new drugs climb, pharma companies are teaming up with AI specialists, hiring data scientists and snapping up tech startups.",
        "body": null
      },
      {
        "uri": "/2018/07/19/novartis-joins-pfizer-in-delaying-price-increases/",
        "title": "Novartis joins Pfizer in delaying price increases",
        "byline": "James Paton",
        "kicker": "News",
        "prettyDate": "July 19, 2018",
        "timeToRead": "1 minute",
        "image": {
          "uri": "https://images.benefitspro.com/contrib/content/uploads/sites/412/2018/04/risinghealthcosts-crop-600x338.jpg",
          "width": "600",
          "height": "338"
        },
        "authors": [
          {
            "webUrl": "/author/profile/james-paton/",
            "name": "James Paton"
          }
        ],
        "kickerNode": [
          {
            "uri": "/news/",
            "sectionName": "News"
          }
        ],
        "summary": "Novartis has voluntarily pulled back on increasing prices in the U.S. to keep the cost of its medicines “reasonable” and “defensible” and to reflect their value for patients.",
        "body": null
      },
      {
        "uri": "/2017/09/22/novartiss-475000-price-on-cancer-therapy-meets-res/",
        "title": "Novartis's $475,000 Price on Cancer Therapy Meets Resistance",
        "byline": " John Lauerman, James Paton ",
        "kicker": "",
        "prettyDate": "September 22, 2017",
        "timeToRead": "3 minute",
        "image": {
          "uri": "",
          "width": "",
          "height": ""
        },
        "authors": [
          {
            "webUrl": "/author/profile/john-lauerman-james-paton/",
            "name": "John Lauerman, James Paton"
          }
        ],
        "kickerNode": [],
        "summary": "The cost of the leukemia treatment,is dramatically higher than other such complex treatments, and the health-care system isnt ready to pay for it.",
        "body": null
      }
    ]
  }
}